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ABSTRACT
Problem In 2009 the National Confidential Enquiry 
into Patient Outcome and Death suggested only 50% 
of patients with acute kidney injury (AKI) receive good 
standards of care. In response National Health Service 
(NHS) England mandated the use of electronic AKI alerts 
within secondary care. However, we recognised AKI is not 
just a secondary care problem, where primary care has 
a crucial role to play in prevention, early detection and 
management as well as post- AKI care.
Methods AKI alerts were implemented in primary and 
secondary care services for a population of 480 000. 
Comparisons were made in AKI incidence, peak creatinine 
following AKI and renal recovery in the years before and 
after using Byar’s approximation (95% CI).
Intervention A complex quality improvement initiative 
was implemented based on the design and integration 
of an AKI alerting system within laboratory information 
management systems for primary and secondary care, 
with an affixed URL for clinicians to access a care bundle 
of AKI guidelines on safe prescribing, patient advice and 
early contact with nephrology.
Results The intervention was associated with an 8% 
increase in creatinine testing (n=32 563). Hospital acquired 
AKI detection increased by 6%, while community acquired 
AKI detection increased by 3% and AKI stage 3 detected 
in primary care fell by 14%. The intervention overall had 
no effect on AKI severity but did improve follow- up testing 
and renal recovery. Importantly hospital AKI 3 recoveries 
improved by 22%. In a small number of AKI cases, the 
algorithm did not produce an alert resulting in a reduction 
in follow- up testing compared with preintervention levels.
Conclusion The introduction of AKI alerts in primary and 
secondary care, in conjunction with access to an AKI care 
bundle, was associated with higher rates of repeat blood 
sampling, AKI detection and renal recovery. Validating 
accuracy of alerts is required to avoid patient harm.
INTRODUCTION
Problem description
Acute kidney injury (AKI) is a common, 
costly and often preventable disorder associ-
ated with significant morbidity and mortality.1 
It is detected in 13%–18% of UK hospital 
admissions and is becoming more common 
in primary care.2 AKI increases the risk of 
developing chronic kidney disease (CKD).3 
A rise in creatinine of ≥500 μmol/L is asso-
ciated with as much as a 6.5- fold increase in 
mortality during inpatient admissions over 
3–7 days.4
In 2009 the UK National Confidential 
Enquiry into Patient Outcome and Death 
published a review examining all cases of 
patients who died in National Health Service 
(NHS) hospitals with a primary diagnosis of 
AKI. The review included 976 deaths across 
216 hospitals and required each case to be 
reviewed by the patient’s managing consul-
tant. It concluded that only 50% of patients 
were considered to have received an overall 
‘good’ standard of care, with the majority of 
care deficit being clinically rather than organ-
isationally mediated. With respect to AKI 
this indicated a lack of recognition; a lack 
awareness of the inherent risk of AKI; a poor 
understanding of the pathophysiology of the 
condition and/or an inadequate knowledge 
of its management among clinicians.1
Available knowledge
In response several NHS hospitals undertook 
quality improvement projects implementing 
automated AKI electronic alerts (AKI alerts) 
together with AKI treatment bundles. These 
interventions pushed AKI alerts to clini-
cians through their blood results reporting 
systems to highlight AKI diagnosis and grade 
severity as well as offer management advice. 
Nottingham University Hospital in 2011 was 
the first to implement an AKI alert system in 
a large NHS hospital, though the impact of 
this intervention was not evaluated.5 In 2012 
University College London Hospital imple-
mented the first primary care AKI alert system, 
though this was only qualitatively assessed 
with primary care practitioners reporting 
it was a useful service that altered practice.6 
In 2013 Aintree University Hospital imple-
mented an alert system within secondary care 
paired with an AKI treatment bundle and 
patient information leaflet reporting large 
quantitative reductions in 30- day mortality, 
length of stay and progression of AKI severity.7 
These projects demonstrated the feasibility 
of implementing AKI alerts pushed to clini-
cians through the laboratory information 
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management systems and in response the 2014 NHS 
England Patient Safety Alert mandated the adoption of 
AKI alert systems via the introduction of a Commissioning 
for Quality and Innovation target (CQUIN) in secondary 
care with adoption in primary care to be considered at 
a later date.8–10 Subsequent publications have generated 
mixed results on the efficacy of AKI alerts on patient 
outcomes.11–14
Rationale
In recognising primary care has a crucial role to play in 
the prevention, early detection and management of AKI, 
as well as post- AKI care, a yearlong quality improvement 
programme to standardise AKI care pathway across the 
trust to include primary care was undertaken prior to the 
adoption of the CQUIN, described in detail by Vaux.15 As 
a result of this, and an extensive cross boundary clinician 
engagement programme, it was felt the system was ready 
for implementation of alerts across both secondary and 
primary care. This context facilitated an evaluation of 
the impact of an AKI alert system across an entire health 
system inclusive of both primary and secondary levels of 
care described in this paper.
Specific aim
To reduce AKI severity and improve renal recovery 
through earlier recognition of AKI, safer prescribing, 
earlier contact with nephrology, improved patient 
follow- up, better provision of patient information and 
where possible community led management of AKI.
METHODS
Context
Four Clinical Commissioning Groups (CCGs) repre-
senting the NHS bodies responsible for commissioning 
care in their region. These included North and West 
Reading CCG, Newbury and District CCG, South Reading 
CCG, Wokingham CCG totalling an area covering 54 
general practices and Royal Berkshire Hospital serving a 
total population of approximately 480 000 patients.
Intervention
In the year prior to the implementation of AKI alerts, an 
innovative intervention used the combination of three 
approaches: information design, human factors and 
quality improvement methodology in the collaborative 
design and development of AKI care bundles (online 
supplemental appendices 1 and 2) to support complex 
clinical decision- making.15 Iterative user and stake-
holder consultation across primary and secondary care 
(including junior doctors, general practitioners (GPs), 
GP out of hours services, hospital and community phar-
macists, consultants, nurses, patients, dieticians, infor-
mation design consultants, human factors specialist) 
was employed to develop a design response that was 
sensitive to user experience and need, culminating in 
simulation testing of a near final prototype. The devel-
opment of supplementary awareness- raising materials, a 
communications and knowledge transfer package built 
around ‘tAKIng care, tAKIng note’, to promote under-
standing of the usefulness of the intervention (in terms 
of benefit to both staff and patients), so ensuring its 
sustainability, alongside face- to- face stakeholder imple-
mentation events using worked through examples helped 
communicate and support care bundle implementation. 
The multi- professional approach using semi- structured 
focus groups, case- based discussion, supported by project 
management support, was transformational in developing 
effective engagement, collaboration and data sharing 
between health professionals within and across the local 
and regional health economy. Easy to access care bundles 
was critical to their use and coimplementation of the new 
approach across primary and secondary care and involved 
both clinicians and laboratory staff. The AKI alerts were 
then implemented for both primary and secondary care 
in June 2015 with AKI incidence data collected the year 
prior to intervention and the year following intervention. 
All learning was reinforced through our 2015/2016 AKI 
CQUIN focused on improving quality of information in 
the discharge letter of a patient who had had an episode 
of AKI during a hospital admission.9 16 This identified that 
educational and awareness initiatives alone were not suffi-
cient in changing practice and mandating user review of 
AKI aftercare information for GPs in patients with AKI 
alerts was necessary for a sustained solution.
Study of the intervention
Anonymised creatinine results were collected for all 
patients over 18 years of age having blood tests performed 
by the Royal Berkshire Hospital biochemistry laboratory 
between July 2014 and October 2016 along with loca-
tion data from which the blood test was requested and 
sampled. This laboratory was the routine service used for 
processing blood results for all 54 primary care practices 
included in the study as well as secondary care facilities. 
No changes were made to NHS standard of care for blood 
taking, transportation, storage or processing of samples.
AKI annual incidence was determined independent 
of the alert system embedded in the laboratory informa-
tion management systems using the 2014 NHS England 
AKI Algorithm Patient Safety Alert.17 Renal function data 
coming from nephrology departments were excluded 
from the analysis. AKI incidence rates per 100 000 popu-
lation were calculated using Byar’s approximation with 
CIs of 95% (95% CI). Peak creatinine was determined as 
the highest creatinine within 30 days of AKI (95% CI). 
Recovery to baseline renal function was determined as 
creatinine values falling within 10% of pre- AKI creatinine 
reached within 90 days (95% CI). Results were stratified by 
location the blood was sampled and requested from; these 
included community hospital inpatient setting=‘Commu-
nity inpatient’; community outpatient setting; =‘Commu-
nity outpatient’; community emergency setting including 
emergency department, acute medical unit and clinical 
decision units=‘ED/AMU/CDU’; hospital inpatient 
settings=‘Hospital inpatient’; primary care=‘General 
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Practice’; and finally hospital outpatient setting=‘Hos-
pital outpatient’. These locales were combined to create 
community acquired and hospital acquired AKI catego-
ries; with community acquired AKI locations including 
community outpatients, community emergency settings, 
primary care and hospital outpatients. Hospital acquired 
AKI refers to inpatient development of AKI in either 
community or hospital inpatients.
RESULTS
In the year following intervention the total number of 
unique individuals undergoing renal function testing 
increased by 9650 (+6%), while total testing increased by 
32 539 tests (+8%). Stratifying results by location shows an 
increase in renal function testing in most locations, with 
the majority of this increase in primary care +10% (20 523 
tests) compared with inpatient testing of only +3% (2460) 
(see table 1).
The implementation of the AKI alerts was associated 
with greater AKI detection of +5% (2500–2613 per 100 000 
population) which when stratified by location shows an 
increase in both hospital acquired AKI of +6% (1432–
1516 per 100 000 population) and community acquired 
AKI of +3% (1068–1096 per 100 000 population). Notably 
AKI stage 3 detection decreased in primary care by −14% 
(31–26 per 100 000 population) with a concomitant 
increase in hospital inpatient AKI 3 detection of +10% 
(202–222 per 100 000 population) (table 2). Aggregated 
results showed an increase in AKI 1 detection of +0.02% 
(1648–1690 per 100 000 population), an increase in AKI 
2 detection of +7.4% (459–493 per 100 000 population) 
and an increase in AKI 3 detection by 9% (393–429 per 
100 000 population) (see table 2).
The effect of the implementation on AKI alerts on peak 
creatinine during AKI was to remain static in all severi-
ties of AKI in all stratified locations with the exception 
of hospital inpatient AKI stage 3 which increased from 
459 μmol/L (440–477) to 535 μmol/L (508–563). Aggre-
gated results show an increase in AKI stage 2 from 243 
μmol/L (234–252) to 262 μmol/L (254–270) and AKI 
stage 3 from 506 μmol/L (489–523) to 548 μmol/L (527–
569) following the implementation of AKI alerts (online 
supplemental table A).
Follow- up renal function testing within 7 days increased 
overall by +5% (76–80 per 100 episodes of AKI) after AKI 
(table 3). Stratification in all locations and in all severity 
categories of AKI mirrored improvement in follow- up 
tests with the most significant improvement in follow- up 
in community outpatient +140% (37–80 per 100 episodes 
of AKI), GP by +38% (37–51 per 100 episodes of AKI) 
and hospital outpatient by +16% (49–57 per 100 episodes 
of AKI). Overall community acquired AKI follow- up 
seemed to benefit more from the implementation of 
AKI alerts than hospital acquired AKI with community 
AKI follow- up improving +11% (63–70 per 100 episodes 
of AKI) compared with +1% (86–87 per 100 episodes of 
AKI) (see table 3).
Renal recovery to within 10% of baseline renal func-
tion improved across all severities of AKI, while follow- up 
tests to 90 days were not affected (online supplemental 
table B). Stratification by location showed most clinically 
significant improvement in recovery in hospital inpa-
tients AKI stage 3, improving by 7.7 cases per 100 AKI 
cases (22% improvement). Community acquired AKI 
recovery improved by 4 cases per 100 (9% improvement) 
and hospital acquired AKI recovery improved by 3.6 cases 
per 100 cases of AKI (7% improvement) (see figure 1 and 
online supplemental table B).
Post hoc analysis of renal function data yielded a 0.55% 
inaccuracy of alerts pushed to clinicians in the study 
due to algorithm failure, including 0.17% (724 per 430 
000 tests) of tests failing to raise an alert for AKI, 0.02% 
(102 per 430 000 tests) of tests underestimating an AKI 
and 0.36% (1553 per 430 000 tests) overestimating AKI 
severity. This provided the opportunity to compare the 
724 patients with AKI that were not pushed alerts to those 
that were in table 3. Overall follow- up creatinine testing 
within 7 days were similar between the groups however 
stratification by location shows differences in community 
acquired AKI follow- up with a reduction of 6.6%. Strati-
fication by AKI severity within the groups showed no real 
difference in AKI 1 follow- up, with 487 out of 609 patients 
followed up (80%), however, AKI 2 and AKI 3 showed 
reductions in follow- up of 25% (only 13 of 33 followed up) 
and 47% (34 of 82 followed up), respectively (table 3).
Table 1 Demographic characteristics of participants and 
number of creatinine tests by location and phase of study
Variables Year 1 Year 2
Population* 478 168 481 381
Unique
individuals†
155 127 164 777




Community inpatient 4239 4807
Community outpatient 863 768
ED/AMU/CDU 47 200 53 769
General practice 203 580 224 103
Hospital inpatient 80 755 82 647
Hospital outpatient 60 964 64 046
Combined community 
locales
312 607 342 686
Combined inpatient 
locales
84 994 87 454
Total 397 601 430 140
Age=mean (95% CI).
*Population derived from Office for National Statistics Clinical 
Commissioning Group population estimates.20
†Number of unique individuals across both study years: 228 903.
ED/AMU/CDU, emergency department, acute medical unit and 
clinical decision units.
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Our results demonstrate that the introduction of an AKI 
alert system in conjunction with an AKI care bundle 
across both primary and secondary care, delivered in the 
context complex quality improvement initiative, resulted 
in significant increases in creatinine testing and AKI 
detection, and importantly improved follow- up and renal 
recovery following AKI.
The system had to be ready for change. Critical to the 
introduction of the AKI alert system was the time taken in 
the preceding year to understand AKI care pathways and 
capture user experience of care bundles across primary 
and secondary care. The foundations for this collabora-
tive work had been built though the then Strategic Clin-
ical Networks, cross boundary working to implement the 
2014 National Institute of Clinical Excellence CKD guide-
lines and quality improvement work with primary care on 
Table 2 Number of cases of AKI per 100 000 patients (95% CI) by location of creatinine testing and phase of study
Location AKI Year 1 Year 2
Community inpatient 1 18.4 (18.3 to 18.5) 17.0 (17.0 to 17.2)
2 5.4 (5.4 to 5.6) 3.7 (3.7 to 3.9)
3 0.8 (0.2 to 2.1) 2.5 (2.4 to 2.6)
Total 24.7 (24.6 to 24.8) 23.3 (23.2 to 23.4)
Community outpatient 1 4.2 (4.1 to 4.3) 3.7 (3.7 to 3.9)
2 1.0 (0.3 to 2.4) 0.4 (0.1 to 1.5)
3 0.4 (0.1 to 1.5) 0.0 (0.0 to 0.8)
Total 5.6 (5.6 to 5.8) 4.2 (4.1 to 4.3)
ED/AMU/CDU 1 334.2 (334.1 to 334.3) 345.5 (345.4 to 345.6)
2 123.4 (123.3 to 123.5) 132.7 (132.7 to 132.9)
3 142.2 (142.1 to 142.3) 151.4 (151.4 to 151.6)
Total 599.8 (599.7 to 599.9) 629.6 (629.6 to 629.8)
General practice 1 220.0 (219.9 to 220.1) 228.7 (228.6 to 228.9)
2 38.7 (38.6 to 38.8) 41.5 (41.5 to 41.7)
3 30.5 (30.5 to 30.7) 26.4 (26.3 to 26.5)
Total 289.2 (289.2 to 289.4) 296.6 (296.6 to 296.8)
Hospital inpatient 1 937.7 (937.7 to 937.9) 978.4 (978.4 to 978.6)
2 267.9 (267.8 to 268.0) 292.7 (292.6 to 292.8)
3 201.8 (201.7 to 202.0) 221.9 (221.8 to 222.0)
Total 1407.5 (1407.4 to 1407.6) 1493.0 (1492.9 to 1493.1)
Hospital outpatient 1 133.8 (133.8 to 134.0) 116.7 (116.7 to 116.9)
2 22.4 (22.3 to 22.5) 21.8 (21.7 to 22.0)
3 17.4 (17.3 to 17.5) 27.2 (27.1 to 27.4)
Total 173.6 (173.5 to 173.7) 165.8 (165.7 to 165.9)
Hospital acquired* 1 956.1 (956.1 to 956.3) 995.5 (995.4 to 995.6)
2 273.3 (273.3 to 273.5) 296.4 (296.4 to 296.6)
3 202.6 (202.6 to 202.8) 224.4 (224.3 to 224.5)
Total 1432.1 (1432.1 to 1432.3) 1516.3 (1516.2 to 1516.4)
Community acquired* 1 692.2 (692.2 to 692.4) 694.7 (694.6 to 694.8)
2 185.5 (185.4 to 185.6) 196.5 (196.4 to 196.7)
3 190.5 (190.4 to 190.7) 205.0 (205.0 to 205.2)
Total 1068.2 (1068.2 to 1068.4) 1096.2 (1096.2 to 1096.4)
All locations* 1 1648.4 (1648.3 to 1648.5) 1690.1 (1690.1 to 1690.3)
2 458.8 (458.8 to 459.0) 493.0 (492.9 to 493.1)
3 393.2 (393.1 to 393.3) 429.4 (429.3 to 429.5)
Total 2500.4 (2500.3 to 2500.5) 2612.5 (2612.4 to 2612.6)
*Aggregated location results.
AKI, acute kidney injury; ED/AMU/CDU, emergency department, acute medical unit and clinical decision units.
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prescribing: polypharmacy, inappropriate and/or exces-
sive prescribing. Trusted and engaged relationships had 
been built across shared visions for change and founded 
on a proven track record of collaborative improvements. 
Case based discussion, worked through examples to bring 
to life use of a care bundle in practice, ease of access to 
any new tools and recognised value of an intervention 
were essential groundwork for readiness of stakeholders 
for the introduction of the AKI alert system.
The AKI alert incidence described in our study popula-
tion is higher than described by Holmes et al in a Welsh 
population and Aiyegbusi et al in a Scottish popula-
tion: 2613 versus 2065 and 2362 AKI alerts per 100 000 
patients, respectively.14 18 The overall association of 
increased creatinine testing and increased AKI detec-
tion following the implementation of electronic alerts 
for AKI is consistent with the findings of Aiyegbusi et al, 
who similarly compared annual AKI incidence data from 
their laboratory information management system pre- 
implementation and post implementation of AKI alerts 
across primary and secondary care in NHS Tayside, Scot-
land. The magnitude of increase in incidence is however 
grossly different, +17% versus our 5%. This could be 
explained by the codesign process of our intervention 
occurring within the pre- implementation comparator 
cohort data collection period, serving to raise practi-
tioner salience to AKI independent of AKI alerts and thus 
to reduce our estimation in the effect of the AKI alert 
intervention alone. The context in which our interven-
tion took place, with a focus on community led manage-
ment of AKI within the care bundle, may also explain the 
gross differences in AKI incidence detected in primary 
care following the implementation, with Aiyegbusi et al 
detecting a 60% reduction in primary care AKI detec-
tion and concomitant 13% increase in AKI admissions, 
compared with our more stable AKI incidences in both 
primary care and locations within the acute admissions 
pathway. This serves to highlight that laboratory informa-
tion management system alerts alone can inadvertently 
redirect patient flows and interventions, as with ours, 
should be designed and implemented to account for this 
or services may require urgent redesign as a result. Our 
data also agree with the direction of improvement in AKI 
follow- up described by Aiyegbusi et al but with similar 
discrepancy in magnitude as outlined previously.14
Table 3 Patients follow- up with blood tests within 7 days per 100 episodes of AKI by AKI severity and location (95% CI)
Variable Year 1 follow- up Year 2 follow- up Year 2 follow- up in patients without alert
AKI 1 73.8 (73.8 to 73.8) 78.2 (78.2 to 78.2) 80.0 (76.6 to 83.0)
AKI 2 81.1 (81.1 to 81.2) 84.5 (84.4 to 84.5) 61.0 (43.7 to 75.3)
AKI 3 78.4 (78.4 to 78.5) 80.1 (80.1 to 80.2) 41.5 (31.4 to 52.3)
Community inpatient 64.4 (64.1 to 65.1) 66.1 (65.7 to 66.8) 61.1 (38.6 to 79.7)
Community outpatient 37.0 (35.7 to 39.6) 80.0 (78.1 to 83.6) 50.0 (9.5 to 90.5)
ED/AMU/CDU 79.6 (79.6 to 79.7) 81.9 (81.9 to 82.0) 73.6 (65.4 to 80.5)
General practice 37.1 (37.1 to 37.2) 50.9 (50.9 to 51.0) 27.4 (18.5 to 38.6)
Hospital inpatient 85.9 (85.9 to 86.0) 87.2 (87.1 to 87.2) 89.9 (86.7 to 92.4)
Hospital outpatient 48.8 (48.7 to 48.9) 57.3 (57.2 to 57.4) 55.2 (43.4 to 66.5)
Hospital acquired* 85.6 (85.5 to 85.6) 86.8 (86.8 to 86.9) 88.7 (85.5 to 91.3)
Community acquired* 63.1 (63.1 to 63.2) 69.8 (69.8 to 69.8) 56.5 (50.5 to 62.2)
All AKI* 76.0 (75.9 to 76.0) 79.7 (79.7 to 79.7) 76.7 (73.4 to 79.6)
*Aggregated location results.
AKI, acute kidney injury; ED/AMUDU, emergency department, acute medical unit and clinical decision units.
Figure 1 Summary data for acute kidney injury (AKI) 
recovery to within 10% of baseline at 90 days per 100 cases 
of AKI wherebloods available within 90 days per by AKI 
location.
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This study is the first of its kind to describe the effect of 
an AKI alert on the primary outcome of renal recovery. 
The vast majority of the literature uses end points such 
mortality, length of stay and requirement for renal 
replacement therapy which are less likely to capture the 
more subtle effects of an AKI alert system, particularly in 
management of less severe AKI.19 Stratification by loca-
tion showed most clinically significant improvement in 
recovery in hospital inpatients AKI stage 3 but with similar 
rates of improvement in renal recovery for community 
and hospital acquired AKIs at all stages.
Finally, our study identified inaccurate AKI alerts in 
<1% of cases, similar to Aiyegbusi et al.14 This provided 
opportunity to compare clinician follow- up behaviour in 
cases by whether an alert was provided. These data suggest 
more severe AKI was less likely to be followed up in the 
cohort without alerts, and concerningly 7- day follow- up 
dropped from pre- implementation levels. This suggests 
that the implementation of inaccurate alerts may cause 
patient harm and any implementation of an electronic 
AKI alert system must undergo a strict quality control 
process to avoid adverse events.
Interpretation
The implementation of an AKI alert system embedded 
into the laboratory information management system 
within primary care yielded similar results to secondary 
care in the improved detection, follow- up and recovery 
from AKI. Implementation of AKI alerts should take place 
in the context of meaningful key stake- holder involve-
ment and clarity in how to respond to alerts. We advocate 
for strict quality control process to validate the accuracy 
of alert algorithms prior to implementation to reduce the 
risk of harm to patients from inaccurate alerts.
Limitations
It is important to highlight the intervention evaluated 
was a complex package of the introduction of AKI alerts 
linked to an AKI care bundle supported by supplemen-
tary awareness- raising materials, a communications and 
knowledge transfer package and therefore external 
validity of the results may be limited by the unique nature 
of this complex intervention. The intervention effects 
on long- term health morbidity and mortality were not 
assessed, instead renal recovery has been used as a surro-
gate marker which is known to be associated with the 
development of CKD, cardiovascular disease, the need for 
chronic dialysis and mortality over time.19 This interven-
tion was conducted in one hospital and its surrounding 
primary care centres, and the results may not generalise 
to other settings. The static post- hoc data analysis is a 
possible source of error where data may not align with 
the dynamic output of a live algorithm running on the 
data as it stood at that point in time. The comparison of 
data to the cohort for which no AKI alerts were received 
were non- randomised and therefore conclusions drawn 
may be biased.
CONCLUSIONS
This study supports the inclusion of primary care in the 
use of AKI alerts. We recommend that the accuracy of 
AKI alert algorithms is validated prior to implementation 
to ensure appropriate management for, and follow- up of 
patients after AKI.
Author affiliations
1Oxford University Clinical Academic Graduate School, NIHR Oxford Biomedical 
Research Centre, Oxford, UK
2Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
3Genomic Epidemiology Branch, Section of Genetics, International Agency for 
Research on Cancer, Lyon, France
4Independent Scholar, London, UK
5Department of Opthalmology, Oxford University Hospitals NHS Trust, Oxford, UK
6Department of Pathology, Royal Berkshire NHS Foundation Trust, Reading, UK
7Department of Health Sciences, Warwick Medical School, University of Warwick, 
Coventry, UK
8Department of Nephrology, Royal Berkshire NHS Foundation Trust, Reading, UK
Twitter Emma Vaux @VauxEmma
Contributors EV was primarily responsible for conceiving, planning and 
implementing the project. MS oversaw data collection and retrieval from the 
laboratory information management system. DL provided strategic oversight for 
project evaluation. JB was primarily responsible for data analysis with KS- B and OS. 
KJ wrote a narrative literature review to inform manuscript write up. JB wrote up 
the project where all authors provided critical insight for manuscript revisions. JB, 
DL and EV are the overall content guarantors.
Funding JB is supported by National Institute for Health Research (NIHR), 
undertaken as part of the Oxford UK Academic Foundation Programme and 
Leicester Academic Clinical Fellowship with no formal grant/award number. DL is 
supported by the NIHR Applied Research Collaboration (ARC) West Midlands and the 
NIHR Community Healthcare MedTech and In Vitro Diagnostics Co- operative (MIC) 
at Oxford Health NHS Foundation Trust.
Disclaimer The views expressed are those of the authors and not necessarily 
those of the NIHR, the NHS or the Department of Health and Social Care.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval This study was conducted as a service evaluation and registered as 
an audit with Royal Berkshire Hospital NHS Foundation Trust. All data extracted from 
the laboratory information management systems was not identifiable to individual 
patients. Only clinical staff had access to routinely collected healthcare data and 
provided anonymised data for analysis by the evaluation team. The intervention 
was a development of clinical service and not a randomised intervention. In order 
to plan future investment in AKI care, the Trust management wished to determine 
if the intervention was associated with an improvement in clinical and process of 
care measures.
Provenance and peer review Not commissioned; internally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Joseph Barker http:// orcid. org/ 0000- 0002- 5483- 9608
 on M










ual: first published as 10.1136/bm





 7Barker J, et al. BMJ Open Quality 2021;10:e000956. doi:10.1136/bmjoq-2020-000956
Open access
REFERENCES
 1 National Confidential Enquiry into Patient Outcome and Death. 
Adding Insult to Injury [Internet].. UK: NCEPOD, 2019: p. 35.. https://
www. ncepod. org. uk/ 2009report1/ Downloads/ AKI_ report. pdf
 2 Acute kidney injury: prevention, detection and management | 
Guidance and guidelines | NICE [Internet].  Nice. org. uk, 2019. 
Available: https://www. nice. org. uk/ guidance/ cg169/ chapter/ 
Introduction#
 3 Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after 
acute kidney injury: a systematic review and meta- analysis. Kidney 
Int 2012;81:442–8.
 4 Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, 
mortality, length of stay, and costs in hospitalized patients. J Am Soc 
Nephrol 2005;16:3365–70.
 5 Porter CJ, Juurlink I, Bisset LH, et al. A real- time electronic alert to 
improve detection of acute kidney injury in a large teaching hospital. 
Nephrology Dialysis Transplantation 2014;29:1888–93.
 6 Alavijeh OS, Bansal J, Hadfield K, et al. Implementation of an 
automated primary care acute kidney injury warning system: a 
quantitative and qualitative review of 2 years of experience. Nephron 
2017;135:189–95.
 7 Chandrasekar T, Sharma A, Chamberlain P, et al. TO023STOP- 
AKIPROJECT: a streamlined approach to AKI management leads 
to reduction OFIN- HOSPITAL mortality, length of stay and AKI 
progression. Nephrology Dialysis Transplantation 2016;31:i70–1.
 8 NHS England. Standardising the early identification of Acute Kidney 
Injury [Internet]. London: Renal Association UK Renal Registry, 
2014: 1. https://www. england. nhs. uk/ patientsafety/ wp- content/ 
uploads/ sites/ 32/ 2014/ 06/ psa- aki2. pdf
 9 NHS England Contracting and Incentives Team Commissioning 
Strategy. Annex A: commissioning for quality and innovation (CQUIN) 
2015/16 guidance templates for use with the NHS standard contract 
2015/16]. London: NHS England, 2015: 1–52. https://www. england. 
nhs. uk/ statistics/ wp- content/ uploads/ sites/ 2/ 2014/ 07/ CQUIN- 
Guidance- 2015- 16- PDF- 641KB. pdf
 10  Thinkkidneys. nhs. uk. Acute kidney injury best practice guidance: 
responding to AKI warning stage test results for adults in primary 
care, 2021. Available: <https://www. thinkkidneys. nhs. uk/ aki/ wp- 
content/ uploads/ sites/ 2/ 2016/ 10/ RespondingtoAKI- Warning- Stage- 
Test- Results- for- Adults- in- Primary- Care. pdf> [Accessed 18 Mar 
2021].
 11 Khandaker M, Taha L, Fairclough C, et al. SO041INCIDENCE 
and mortality of patients with acute kidney injury in hospitalised 
patients using the NHS England AKI algorithm. Nephrology Dialysis 
Transplantation 2016;31:i18–19.
 12 Lachance P, Villeneuve P- M, Rewa OG, et al. Association 
between e- alert implementation for detection of acute kidney 
injury and outcomes: a systematic review. Nephrol Dial Transplant 
2017;32:gfw424.
 13 West Midlands Acute Medicine Collaborative. The impact of the NHS 
electronic- alert system on the recognition and management of acute 
kidney injury in acute medicine. Clin Med 2019;19:109–13.
 14 Aiyegbusi O, Witham MD, Lim M, et al. Impact of introducing 
electronic acute kidney injury alerts in primary care. Clin Kidney J 
2019;12:253–7.
 15 Vaux E. Designing care bundle documentation to support the 
recognition and treatment of acute kidney injury: a route to quality 
improvement, in design for health. In: Tsekleves E, Cooper R, eds. 
Design for health. Taylor & Francis Ltd, 2017: 170–90.
 16 Reschen ME, Vaux E. Improving the completeness of acute kidney 
injury follow- up information in hospital electronic discharge letters. 
BMJ Open Qual 2017;6:e000022.
 17 NHS England. Algorithm for detecting Acute Repeat Kidney Injury 
(AKI) based on serum creatinine changes with time [Internet]. 
London: Renal Association, UK Renal Registry, 2014: 1. https://www. 
england. nhs. uk/ wp- content/ uploads/ 2014/ 06/ psa- aki- alg. pdf
 18 Holmes J, Rainer T, Geen J, et al. Acute kidney injury in the era of the 
AKI E- Alert. Clin J Am Soc Nephrol 2016;11:2123–31.
 19 Forni LG, Darmon M, Ostermann M, et al. Renal recovery after acute 
kidney injury. Intensive Care Med 2017;43:855–66.
 20  Ons. gov. uk. Clinical commissioning group population estimates 
(National Statistics) - Office for National Statistics, 2019. Available: 
https://www. ons. gov. uk/ peop lepo pula tion andc ommunity/ popu lati 
onan dmig ration/ populationestimates/ datasets/ clin ical comm issi onin 
ggro upmi dyea rpop ulat ione stimates [Accessed 23 Nov 2019].
 on M










ual: first published as 10.1136/bm
joq-2020-000956 on 10 M
ay 2021. D
ow
nloaded from
 
